News

4SC: Yakult Honsha joins pivotal RESMAIN study of resminostat in CTCL

Details

4SC AG today announced that Yakult Honsha Co. Ltd., 4SC’s development partner for resminostat in Japan, opens additional clinical centers in Japan and contributes patients to the RESMAIN study. Additionally, 4SC received a milestone payment. 

CEPI partners with Themis to advance vaccines against Lassa fever and MERS

Details

Today Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a partnership under which Themis will provide advanced vaccine development and manufacturing for Lassa fever and MERS. The investment of up to $37,500,000 represents an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak. 

Themis establishes Scientific Advisory Board of experts in virology and vaccine development

Details

Themis has established a Scientific Advisory Board (SAB) with the appointment of Christian W. Mandl, Ph.D., MD, W. Paul Duprex, Ph.D., Stephen J. Thomas, MD and Nadia G. Tornieporth, MD. The newly-formed SAB brings a wealth of experience in molecular virology, viral pathogenesis and vaccine development. The purpose of the SAB will be to advise Themis as it continues to develop its pipeline of urgently needed vaccines and immune system activation approaches. 

  1. Physicians at Helios gain access to Amboss platform
  2. Immatics appoints Thomas Ulmer as Chief Financial Officer
  3. Themis raises EUR 10 million in Series C financing to advance clinical pipeline
  4. Themis presents Phase II interim results for Chikungunya vaccine candidate at ASTMH 2017
© Wellington Partners, 2018.